These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38824166)

  • 1. Highly biased agonism for GPCR ligands via nanobody tethering.
    Sachdev S; Creemer BA; Gardella TJ; Cheloha RW
    Nat Commun; 2024 Jun; 15(1):4687. PubMed ID: 38824166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly biased agonism for GPCR ligands via nanobody tethering.
    Sachdev S; Creemer BA; Gardella TJ; Cheloha RW
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved GPCR ligands from nanobody tethering.
    Cheloha RW; Fischer FA; Woodham AW; Daley E; Suminski N; Gardella TJ; Ploegh HL
    Nat Commun; 2020 Apr; 11(1):2087. PubMed ID: 32350260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism.
    Bohinc BN; Gesty-Palmer D
    Mini Rev Med Chem; 2012 Aug; 12(9):856-65. PubMed ID: 22681253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.
    Shonberg J; Lopez L; Scammells PJ; Christopoulos A; Capuano B; Lane JR
    Med Res Rev; 2014 Nov; 34(6):1286-330. PubMed ID: 24796277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive Activation Mechanism for Angiotensin Receptor Revealed by a Synthetic Nanobody.
    Wingler LM; McMahon C; Staus DP; Lefkowitz RJ; Kruse AC
    Cell; 2019 Jan; 176(3):479-490.e12. PubMed ID: 30639100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conserved class B GPCR activation by a biased intracellular agonist.
    Zhao LH; He Q; Yuan Q; Gu Y; He X; Shan H; Li J; Wang K; Li Y; Hu W; Wu K; Shen J; Xu HE
    Nature; 2023 Sep; 621(7979):635-641. PubMed ID: 37524305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.
    Luttrell LM; Maudsley S; Bohn LM
    Mol Pharmacol; 2015 Sep; 88(3):579-88. PubMed ID: 26134495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergent biological properties of arrestin pathway-selective biased agonism.
    Appleton KM; Luttrell LM
    J Recept Signal Transduct Res; 2013 Jun; 33(3):153-61. PubMed ID: 23448506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
    Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
    Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption.
    Bohinc BN; Gesty-Palmer D
    Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):112-9. PubMed ID: 21476967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating in vitro ligand bias into in vivo efficacy.
    Luttrell LM; Maudsley S; Gesty-Palmer D
    Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
    Luttrell LM
    Mol Endocrinol; 2014 Mar; 28(3):281-94. PubMed ID: 24433041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actions of the small molecule ligands SW106 and AH-3960 on the type-1 parathyroid hormone receptor.
    Carter PH; Dean T; Bhayana B; Khatri A; Rajur R; Gardella TJ
    Mol Endocrinol; 2015 Feb; 29(2):307-21. PubMed ID: 25584411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semi-synthetic nanobody-ligand conjugates exhibit tunable signaling properties and enhanced transcriptional outputs at neurokinin receptor-1.
    Braga Emidio N; Cheloha RW
    Protein Sci; 2024 Feb; 33(2):e4866. PubMed ID: 38088474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric coupling and biased agonism in G protein-coupled receptors.
    Bock A; Bermudez M
    FEBS J; 2021 Apr; 288(8):2513-2528. PubMed ID: 33621418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?
    Gesty-Palmer D; Luttrell LM
    Br J Pharmacol; 2011 Sep; 164(1):59-67. PubMed ID: 21506957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential.
    Seyedabadi M; Ghahremani MH; Albert PR
    Pharmacol Ther; 2019 Aug; 200():148-178. PubMed ID: 31075355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agonist-selective recruitment of engineered protein probes and of GRK2 by opioid receptors in living cells.
    Stoeber M; Jullié D; Li J; Chakraborty S; Majumdar S; Lambert NA; Manglik A; von Zastrow M
    Elife; 2020 Feb; 9():. PubMed ID: 32096468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot the pulse: controlling the multiplicity of receptor dynamics.
    Bock A; Kostenis E; Tränkle C; Lohse MJ; Mohr K
    Trends Pharmacol Sci; 2014 Dec; 35(12):630-8. PubMed ID: 25455830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.